9-(3-deoxy-3-fluoro-β-D-xylofuranosyl)guanine | 125291-15-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 9-(3-deoxy-3-fluoro-β-D-xylofuranosyl)guanine
• 英文别名: 6H-Purin-6-one, 2-amino-9-(3-deoxy-3-fluoro-beta-D-xylofuranosyl)-1,9-dihydro-；2-amino-9-[(2R,3S,4R,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
• CAS: 125291-15-8
• 化学式: C₁₀H₁₂FN₅O₄
• 分子量: 285.235
• InChiKey: VDOWHLFGBWKXJC-AYQXTPAHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  135
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  9-(3-deoxy-3-fluoro-β-D-xylofuranosyl)guanine 在 溴 作用下， 以 水 为溶剂， 以76%的产率得到2-amino-8-bromo-9-((2R,3S,4R,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one
  参考文献：
  名称：

  TLR7 AGONISTS

  摘要：

  本发明涉及按照式I的TLR7激动剂及其在治疗癌症和传染病等疾病中的应用。

  公开号：

  US20190359613A1
• 作为产物：
  描述：

  1,2-O-异丙基-α-D-呋喃核糖 在 苯磺酰胺 、 4-二甲氨基吡啶 、 二乙胺基三氟化硫 、 TMSTf 、 硫酸 、 氨 、 一水合肼 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 9-(3-deoxy-3-fluoro-β-D-xylofuranosyl)guanine
  参考文献：
  名称：

  Synthesis of 9-(3-deoxy- and 2,3-dideoxy-3-fluoro-β-D-xylofuranosyl)guanines as potential antiviral agents

  摘要：

  DOI：

  10.1016/s0040-4039(00)99193-7

文献信息

• Oligonucleotides having chiral phosphorus linkages
  申请人：——

  公开号：US20020137921A1

  公开（公告）日：2002-09-26

  Sequence-specific oligonucleotides are provided having substantially pure chiral Sp phosphorothioate, chiral Rp phosphorothioate, chiral Sp alkylphosphonate, chiral Rp alkylphosphonate, chiral Sp phosphoamidate, chiral Rp phosphoamidate, chiral Sp phosphotriester, and chiral Rp phosphotriester linkages. The novel oligonucleotides are prepared via a stereospecific SN 2 nucleophilic attack of a phosphodiester, phosphorothioate, phosphoramidate, phosphotriester or alkylphosphonate anion on the 3′ position of a xylonucleotide. The reaction proceeds via inversion at the 3′ position of the xylo reactant species, resulting in the incorporation of phosphodiester, phosphorothioate, phosphoramidate, phosphotriester or alkylphosphonate linked ribofuranosyl sugar moieties into the oligonucleotide.

  提供具有高度纯度手性Sp磷酸硫酯、手性Rp磷酸硫酯、手性Sp烷基膦酸酯、手性Rp烷基膦酸酯、手性Sp磷酰胺酸酯、手性Rp磷酰胺酸酯、手性Sp磷酸三酯和手性Rp磷酸三酯连接的序列特异性寡核苷酸。通过对木糖核苷酸的3'位点进行立体特异性的SN2亲核攻击，制备了这种新型寡核苷酸。反应通过在木糖反应物种的3'位点进行反转进行，导致将磷酸二酯、磷酸硫酯、磷酸胺酰酯、磷酸三酯或烷基膦酸酯连接的核糖核苷酸单元并入寡核苷酸中。
• CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION
  申请人：Invivogen

  公开号：EP3505527A1

  公开（公告）日：2019-07-03

  The present invention concerns compounds of Formula (I) or Formula (II). wherein X2 is H or F; Z1 and Z2 are independently O or S; R1 and R2 are independently H or an enzyme-labile group which, together with the oxygen atom or sulfur atom to which it is attached, provides OH or SH in vivo such as pivaloyloxymethyl or acyloxybenzyl group; A1 is O-R3 or NH-R3; A2 is O-R3' or NH-R3'; B1 is H, NH-R4 or an halogen such as F, Cl, Br, I; B2 is H, NH-R4' or an halogen such as F, Cl, Br, I; R3, R3', R4 and R4' are independently H or an enzyme-labile group which, together with the oxygen atom or sulfur atom to which it is attached, provides OH or NH2 in vivo such as pivaloyloxymethyl, or a pharmaceutically acceptable salt, stereoisomer, tautomer or solvate thereof, except a compound of Formula (I) wherein X2 = F, Z1 = Z2= O, R1 = R2= R3= H, A2 = OH and B2 = H. The invention also concerns pharmaceutical compositions comprising said cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer.

  本发明涉及式（I）或式（II）化合物。 其中 X2 是 H 或 F；Z1 和 Z2 独立地是 O 或 S；R1 和 R2 独立地是 H 或与所连接的氧原子或硫原子一起在体内提供 OH 或 SH 的酶抑制基团，例如新戊酰氧基甲基或酰氧基苄基；A1 是 O-R3 或 NH-R3；A2 是 O-R3' 或 NH-R3'；B1是H、NH-R4或卤素，如F、Cl、Br、I； B2是H、NH-R4'或卤素，如F、Cl、Br、I； R3、R3'、R4和R4'独立地是H或与所连接的氧原子或硫原子一起在体内提供OH或NH2的酶抑制基，如新戊酰氧基甲基、 或其药学上可接受的盐、立体异构体、同分异构体或溶媒、 式（I）化合物除外，其中 X2 = F，Z1 = Z2= O，R1 = R2= R3= H，A2 = OH 和 B2 = H。 本发明还涉及包含上述环二核苷酸的药物组合物，以及它们在治疗细菌感染、病毒感染或癌症中的用途。
• Substituted purines as TLR7 agonists
  申请人：Primmune Therapeutics, Inc.

  公开号：US11059824B2

  公开（公告）日：2021-07-13

  The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease.

  本发明涉及根据式 I 的 TLR7 激动剂及其在治疗癌症和传染病等疾病中的用途。
• Synthesis of 9-(3-deoxy- and 2,3-dideoxy-3-fluoro-β-D-xylofuranosyl)guanines as potential antiviral agents
  作者：Frédéric Puech、Gilles Gosselin、Jean-Louis Imbac

  DOI：10.1016/s0040-4039(00)99193-7

  日期：——
• PUECH, FREDERIC;GOSSELIN, GILLES;IMBACH, JEAN-LOUIS, TETRAHEDRON LETT., 30,(1989) N4, C. 3171-3174
  作者：PUECH, FREDERIC、GOSSELIN, GILLES、IMBACH, JEAN-LOUIS

  DOI：——

  日期：——